A Closed-loop Assessment and Treatment Platform for Unipolar Depression and Anxiety
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02948036|
Recruitment Status : Recruiting
First Posted : October 28, 2016
Last Update Posted : August 10, 2021
Specific Aim 1: Finalize development of the closed-loop strategy in the MMT application.
Specific Aim 2: Evaluate the acceptability and feasibility of the MMT application with the target population to prepare for a large-scale efficacy trial.
|Condition or disease||Intervention/treatment||Phase|
|Major Depressive Disorder||Other: Mobile-device, plasticity-based adaptive cognitive treatment||Not Applicable|
Specific Aim 1: Investigators have recently constructed a beta version of the MMT application, comprised of the multi-modal assessment modules, several treatment modules and an initial version of the closed-loop algorithm to control treatment delivery. Utilizing the extensive experience in developing mobile assessment and treatment tools at Posit Science Corporation, the investigators will employ an iterative development process incorporating feedback from users (focus groups of patients with mood disorders), clinicians and scientists (project consultants) to achieve the following development goals: (1) Finalize MMT's closed-loop algorithm to incorporate all assessment modules and expand the existing triage approach; (2) Expand cognitive behavioral therapy (CBT) functions within the app; and (3) Expand in-app bi-directional communication feature between the clinician and user. At the completion of Specific Aim 1, the investigators will have a mobile app suitable for evaluation in a feasibility trial (Specific Aim 2).
Specific Aim 2: The investigators will conduct a single arm, open label feasibility field trial with 30 participants that meet criteria for Major Depressive Disorder (MDD). Participants will be asked to engage with the experimental cognitive treatment and spend up to six weeks engaged in 15 hours of cognitive training as an adjunct to their standard clinical treatment. The experimental cognitive treatment will be deployed as dictated by the closed loop predictive algorithm, with all patient data continuously accessible for remote monitoring by the attending clinicians, research staff and Principal Investigator at University of Minnesota, and research staff and Sponsor PI at Posit Science Corporation. Participants will be re-evaluated every two weeks during treatment use, and again at the expected time of completion of training, at 6 weeks, to evaluate changes in cognitive function. Participants will then stop using their assigned program for 6 weeks, and return for a follow-up assessment to evaluate the endurance of changes in cognitive function in the absence of further program use.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Closed-loop Assessment and Treatment Platform for Unipolar Depression and Anxiety|
|Actual Study Start Date :||October 1, 2017|
|Estimated Primary Completion Date :||May 31, 2022|
|Estimated Study Completion Date :||May 31, 2022|
Mobile-device, plasticity-based adaptive cognitive treatment
Other: Mobile-device, plasticity-based adaptive cognitive treatment
This study employs a mobile-device delivered treatment program. Participants will be asked to use the assigned treatment program for approximately 30 minutes per session, up to seven sessions per week, over 6 weeks (42 total sessions).
Other Name: MMT
- Change in total score for depressive symptoms using Beck Depression Scale (BDI-II) [ Time Frame: At 2 weeks, 4 weeks, 6 weeks and at 12 weeks ]The Beck Depression Scale (BDI-II) is a self-report questionnaire that assesses depressive symptoms with a scoring range between 0-63.
- Change in total score for depressive symptoms using Patient Health Questionnaire (PHQ-9) [ Time Frame: At 2 weeks, 4 weeks, 6 weeks and at 12 weeks ]The Patient Health Questionnaire (PHQ-9) is a self-report questionnaire that assesses the degree of depression severity with a scoring range between 0-27.
- Change in total score for anxiety symptoms using Generalized Anxiety Disorder (GAD-7) [ Time Frame: At 2 weeks, 4 weeks, 6 weeks and at 12 weeks ]The Generalized Anxiety Disorder (GAD-7) is a self-reported questionnaire for screening and severity measuring of generalized anxiety disorder with a scoring range between 0-21.
- Change in total score for mood symptoms using Immediate Mood Scaler (IMS) [ Time Frame: At 2 weeks, 4 weeks, 6 weeks and at 12 weeks ]The Immediate Mood Scaler (IMS) is a clinical assessment that assesses momentary mood symptoms related to anxiety and depression with a scoring range between 22-181.
- Change in total score for quality of life using the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) [ Time Frame: At 2 weeks, 4 weeks, 6 weeks and at 12 weeks ]The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) assesses the degree of enjoyment and satisfaction experienced in various areas of daily functioning with a scoring range between 0-70.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02948036
|Contact: Sarah-Jane Kimemail@example.com|
|United States, Minnesota|
|University of Minnesota||Recruiting|
|Minneapolis, Minnesota, United States, 55454|
|Contact: Sasha Mochida 612-403-4587 firstname.lastname@example.org|
|Principal Investigator: Gamze Camsari, MD|
|Principal Investigator:||Gamze Camsari, MD||University of Minnesota - Department of Psychiatry|
|Principal Investigator:||Thomas Van Vleet, PhD||Posit Science Corporation|